Impact of baseline CD4 count, immune recovery and viral suppression at 1 year of first highly active antiretroviral therapy on survival, AIDS defining events and immune recovery reactions;Impacto de la inmunodepresión basal y su grado de recuperación al año de terapia antirretroviral en sobrevida, complicaciones oportunistas y reacción de recuperación inmune

Revista Medica de Chile

Volumn 136, Issue 12, 2008, Pages 1503-1510

  Cortés, Claudia ^a,b   Beltrán, Carlos ^a,c   Muñoz, Rodrigo ^a   Daube, Elizabeth ^a   Wolff, Marcelo ^a,b  

^a Grupo SIDA Chile   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c UNIVERSIDAD DE SANTIAGO DE CHILE   (Chile)

Author keywords

Acquired immunodeficiency syndrome; Antiretroviral therapy; CD4 cell counts; Highly active

Indexed keywords

AIDS RELATED COMPLEX; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG EFFECT; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MORTALITY; PROSPECTIVE STUDY; VIRUS LOAD; AIDS-RELATED OPPORTUNISTIC INFECTIONS; DRUG EFFECTS; HIV INFECTIONS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 62849118322     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F et al from ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-29.
2. Opravil M, Ledergerber B, Furrer H, Hirschel B, Imhof A, Gallant S et al from the Swiss HIV Cohort Study. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l. AIDS 2002; 16: 1371-81.
3. Chêne G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN et al from ART Cohort Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362: 679-86.
4. Wolff M, Diomedi A, Dabanch J, Bidart, Bustamante C, Morales O et al. Seguimiento prospectivo de una población infectada por VIH con y sin posibilidades de terapia antirretroviral: impacto en sobrevida y complicaciones (EFITAR). Rev Méd Chile 2001; 129: 886-94.
5. Wolff M, Alvarez P, Flores I, Northland R, Wolff C. Evolución de mortalidad y estado actual de una población infectada por VIH controlada en un centro multiprofesional. Rev Méd Chile 2006; 134: 581-8.
6. Hoffman R, Currier S. Management of Antiretroviral Treatment-Related Complications. Infect Dis Clin North Am 2007; 21: 103-32.
7. Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP, Kumarasamy N. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 2007; 45: 1093-101.
8. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; Suppl 1: S5-14.
9. Schechter M, Tuboi SH. Discordant immunological and virological responses to antiretroviral therapy. J Antimicrob Chemother 2006; 58: 506-10.
10. Valdez H, Connick E, Smith KY, Lederman MM, Bosch RJ, Kim RS et al for the AIDS Clinical Trials Group Protocol 375 Team. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16: 1859-66.
11. Hammer S, Saag M, Schechter M, Montaner J, Schooley R, Jacobsen D et al. Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society-USA Panel. JAMA 2006; 296: 827-43.
12. Mcilleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 2007; SUPPL 1: S63-75.
13. Dunic I, Djurkovic-Djakovic O, Vesic S, Zerjav S, Jevtovic D. Herpes zoster as an immune restoration disease in AIDS patients during therapy including protease inhibitors. Int J STD AIDS 2005; 16: 475-8.
14. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(RR-17): 1-19.
15. Wolff MJ, Beltrán C, Vásquez P, Ayala M, Valenzuela M, Berrios G et al for the Chilean Aids Group. The Chilean AIDS cohort: a model for evaluating the impact of an expanded access program to antiretroviral therapy in a middle-income country-organization and preliminary results. J Acquir Immune Defic Syndr 2005; 40: 551-7.
16. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
17. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC et al for the ART Cohort Collaboration. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006; 368: 451-8.
18. sr Ed. Santiago: Minsal 2005.